1Zhang GZ, Jiao SC, Meng ZT. Pemetrexed plus cisplatin/ carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients[J]. J Exp Clin Cancer Res,2010,29:38.
2Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-celllung cancer[J]. Clin Oneol, 2008,26(1):4270-4277.
3Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer[J]. J Clin Oneol,2007,25(27) :4270 -4277.
4Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial[J]. J Clin Oncol,2009,27(20) :3312-3318.
5Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol,2010,11(2) : 121-128.
5Folkman J. Role of angiogenesis in tumor growth and metastasis.Semin Oncol,2002,29(6 Suppl 16) : 15-18.
6Huang X, Wong MK, Zhao Q, et al. Soluble recombinant endostatinpurified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res,2001,61(2): 478-481. Erratum in:Cancer Res, 2001,61 ( 15 ) : 5956. Cancer Res, 2001,61 (10) :4297.
7Li B, Wu XY, Zhou H, et al. Acid-induced unfolding mechanism of recombinant human endostatin. Biochemistry, 2004, 43 (9) :2550-2557.
8Eder JP Jr, Supko JG, Clark JW, et al. Phase Ⅰ clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol, 2002,20(18) : 3772-3784.
9Kulke M, Bergsland E, Ryan DP, et al. A phase Ⅱ , open-label,safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc ASCO,2003,22: 958a.
10Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced nonsmall cell lung cancer. J Clin Oncol,2002,20(21) : 4285-4291.
9Ferlay J,Shin HR,Bray F,et al.Estimates of worldwide burden of cancer in2008:GLOBOCAN2008[J].Int J Cancer,2010,127(12):2893.
10Cappuzzo F,Hirsch FR,Rossi E,et al.Epidermal grow-th factor receptor gene and protein and gefitinib sensitivi-ty in non-small-cell lung cancer[J].J Nat Cancer Insti-tute,2005,97(9):643.
